Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant

NCT02668172 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT02668172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02668172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant
Lead sponsor
Erasmus Medical Center
Phase
Phase 4
Overall status
Unknown status
Start date
August 31, 2015
Completion date
June 30, 2017
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly